首页 | 本学科首页   官方微博 | 高级检索  
     

司帕沙星对比氧氟沙星治疗耐多药肺结核的系统评价
引用本文:余文韬,符丽,周俊翔,唐尧. 司帕沙星对比氧氟沙星治疗耐多药肺结核的系统评价[J]. 华西医学, 2011, 0(10): 1491-1495
作者姓名:余文韬  符丽  周俊翔  唐尧
作者单位:四川大学华西医院药剂科
摘    要:目的系统评价司帕沙星对比氧氟沙星治疗耐多药肺结核的有效性和安全性。方法计算机检索Cochrane图书馆临床对照试验资料库(2010年第2期)和PubMed(1978年一2010年10月)、EMBASE(1974年一2010年10月)、中国学术期刊网络出版总库(1978年一2010年10月)、维普(1989年一2010年10月)、中国生物医学文献数据库(1978年一2010年10月);手工检索其他相关杂志。检索语种为中文和英文。纳入司帕沙星对比氧氟沙星治疗耐多药肺结核的随机对照试验。按Cochrane系统评价的方法评价纳入研究质量,用RevMan5.0软件对数据进行Meta分析。结果共纳入8篇研究,Meta分析结果显示司帕沙星组与氧氟沙星组相比,痰菌转阴率、病灶显著吸收率、空洞闭合率均高于对照组,差异具有统计学意义(P〈0.05)。结论现有的证据表明,司帕沙星与其他抗结核药物联用治疗难治、耐多药肺结核的疗效优于氧氟沙星的联用方案,但由于纳入的文献数量有限,质量参差不齐,存在潜在的发表偏倚。

关 键 词:司帕沙星  氧氟沙星  耐多药肺结核  系统评价

Systematic Review of Sparfloxacin versus Ofloxacin in Treatment of Multi-drug Resistant Pulmonary Tuberculosis
YU Wen-tao,FU Li,ZHOU Jun-xiang,TANG Yao. Systematic Review of Sparfloxacin versus Ofloxacin in Treatment of Multi-drug Resistant Pulmonary Tuberculosis[J]. West China Medical Journal, 2011, 0(10): 1491-1495
Authors:YU Wen-tao  FU Li  ZHOU Jun-xiang  TANG Yao
Affiliation:.Department of Pharmacy,West China Hospital,Sichuan University,Chengdu,Sichuan 610041,P.R.China
Abstract:Objective To assess the clinical efficacy and safety of sparfloxacin versus ofloxacin in treatment of multi-drug resistant pulmonary tuberculosis (MDR-TB). Methods Literatures were retrieved from PubMed (1978- October, 2010), EMBASE (1974-October 2010), Cochrane library (2nd volume, 2010), China Academic Journal Network Publishing Database (1978-October, 2010), VIP (1989-October, 2010) and CBM (1978 to October, 2010) by computer, and searched some other relevant journals manually. Chinese and English were both used in the search. Randomized controlled trials (RCTs) on sparfloxacin versus ofloxacin in treating pulmonary tuberculosis were included in this study. Meta-analysis was conducted by RevMan 5.0 software. Results The meta-analysis of 8 included RCTs showed that the sputum negative conversion rate, focus absorption rate, cavity closure rate in the sparfloxacin group were significantly higher than the ofloxacin group (P~0. 05). Conclusions The analysis indicates that combined treatment with sparfloxacin has a better effect in treating MDR-TB than with ofloxacin. However, the reliability of this review may be affected by the number and quality of studies included. Large-scale randomized controlled trials of high quality are needed to confirm the conclusions above.
Keywords:Sparfloxacin  O{loxacin  Multi-drug resistant tuberculosis~ Systematic review
本文献已被 CNKI 维普 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号